Jupiter Biomedical Research
Palm Beach Gardens, US · Founded 2016 · Florida corporation
Jupiter Biomedical Research develops two drug candidates: JBR-102, a new chemical entity in preclinical studies for glioblastoma and other solid tumor and hematologic cancers, and JBR-201, an antiviral therapeutic tested against measles, herpes, and other viruses. The company focuses on commercializing these oncology and antiviral treatments.
Founders & leadership
RC
Robert C. HackneyExecutive
RP
Richard P. TamboneExecutive
FG
Frank GerardiExecutive
RT
Richard TamboneExecutive
CH
Charles H. BurnsExecutive
JF
John FanarasNamed on SEC filing
WG
William G. TuckerNamed on SEC filing
VT
Vivian TuckerNamed on SEC filing
Board
TS
Tipton ShonkwilerBoard director
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 4 rounds · 2017–2026
▶$500KraisedMay 2026 · 30 investors · BiotechnologyRule 506(b)
▶$500KraisedMay 2026 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tipton ShonkwilerDirector
- David VaughanDirector
- Robert C. HackneyExecutive Officer, Director
- Frank GerardiExecutive Officer, Director
- John FanarasExecutive Officer, Director
- Richard P. TamboneExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $5K
- First sale
- Feb 2026
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b, 4a5
▶$500KraisedNov 2025 · 27 investors · BiotechnologyRule 506(b)
▶$500KraisedNov 2025 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John FanarasExecutive Officer, Director
- Robert C. HackneyExecutive Officer, Director
- Tipton ShonkwilerDirector
- Richard P. TamboneExecutive Officer, Director
- Frank GerardiExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $5K
- First sale
- Jun 2025
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b, 4a5
▶$625KraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$625KraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank GerardiExecutive Officer, Director, Promoter
- William G. TuckerExecutive Officer, Director, Promoter
- Richard P. TamboneExecutive Officer, Director, Promoter
- Kingsley WardDirector
- John FanarasDirector
- Robert C. HackneyDirector
- Charles H. BurnsExecutive Officer, Director, Promoter
- Amount sold
- $625K
- Minimum investment
- $25K
- First sale
- Oct 2020
- Incorporated
- Corporation, Florida, 2016
- Federal exemptions
- 06b
▶$500KraisedApr 2017 · 10 investors · BiotechnologyRule 506(b)
▶$500KraisedApr 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank GerardiDirector
- William G. TuckerExecutive Officer, Director, Promoter
- Richard TamboneExecutive Officer, Director
- Charles H. BurnsExecutive Officer, Director
- Vivian TuckerExecutive Officer, Director, Promoter
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- First sale
- Jan 2017
- Incorporated
- Corporation, Florida, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Jupiter Biomedical Research for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Jupiter Biomedical Research do?
- Jupiter Biomedical Research develops two drug candidates: JBR-102, a new chemical entity in preclinical studies for glioblastoma and other solid tumor and hematologic cancers, and JBR-201, an antiviral therapeutic tested against measles, herpes, and other viruses. The company focuses on commercializing these oncology and antiviral treatments.
- How much funding has Jupiter Biomedical Research raised?
- Jupiter Biomedical Research has disclosed $2.1M raised across 4 rounds.
- Where is Jupiter Biomedical Research headquartered?
- Jupiter Biomedical Research is headquartered in Palm Beach Gardens, US.
